Thousands of people living with cystic fibrosis in England face an uncertain wait for life-changing treatments after the drugs watchdog provisionally rejected three breakthrough therapies on cost grounds. The National Institute for Health and Care Excellence (NICE) has published draft guidance recommending against the routine use of elexacaftor/tezacaftor/ivacaftor, tezacaftor/ivacaftor, and ivacaftor within the NHS, citing concerns that manufacturer Vertex Pharmaceuticals' pricing does not represent value for money.
These treatments represent a significant advance in cystic fibrosis care, targeting the underlying genetic defects that cause the condition rather than simply managing symptoms. Cystic fibrosis is a severe, life-limiting genetic condition affecting the lungs and digestive system, causing recurrent infections and progressive organ damage. More than 10,000 people across the UK live with the condition, which typically reduces life expectancy to around 47 years.
Clinical trials have demonstrated that these drugs can meaningfully improve lung function and reduce the frequency of serious chest infections that characterise the condition. However, NICE's provisional decision centres on the substantial cost of the treatments, which can exceed £100,000 per patient annually.
If the draft guidance becomes final, these medicines would not be routinely available through the NHS in England, potentially denying access to treatments that patient groups describe as transformative. The Cystic Fibrosis Trust and other charities have consistently campaigned for broader access to these innovative therapies, emphasising their potential to significantly improve both quality of life and survival rates.
This marks another chapter in ongoing tensions between NICE and Vertex Pharmaceuticals over cystic fibrosis drug pricing. Previous negotiations for similar treatments have involved lengthy discussions and public pressure campaigns before reaching resolution. The pharmaceutical company has expressed disappointment with the draft guidance whilst reaffirming its commitment to working with NICE and the NHS.
The Shadow Health Secretary has called on the government to ensure patients with life-limiting conditions are not denied access to potentially life-changing treatments due to pricing disputes, urging all parties to prioritise patient needs in reaching a swift resolution.
A consultation period is now open, allowing patient groups, clinicians, and the manufacturer to submit additional evidence and feedback. This represents a crucial opportunity for stakeholders to influence the final decision, which will ultimately determine access to these treatments for thousands of patients across England.